 |
|
 |
-
Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor velcade (bortezomib, PS-341).
Publish date: 7 May 2008.
Author(s): Kamer S, Ren Q, Dicker AP
Arch Gynecol Obstet;
Pages: ;
Abstract
-
In vivo Investigations on Anti-fibrotic Potential of Proteasome Inhibition in Lung and Skin Fibrosis.
Publish date: 5 May 2008.
Author(s): Fineschi S, Bongiovanni M, Donati Y, Djaafar S, Naso F, Goffin L, Barazzone Argiroffo C, Pache JC, Dayer JM, Ferrari-Lacraz S, Chizzolini C
Am J Respir Cell Mol Biol;
Pages: ;
Abstract
-
Small-molecule inhibition of proteasome and silencing by vascular endothelial cell growth factor-specific siRNA induce additive antitumor activity in multiple myeloma.
Publish date: 5 May 2008.
Author(s): Koldehoff M, Beelen DW, Elmaagacli AH
J Leukoc Biol;
Pages: ;
Abstract
|
|
| More abstracts |
|
|
|
|
 |
Company news
16/01/2006
Millennium has presented positive phase III survival data for VELCADE® (bortezomib) in multiple myeloma.
More...
28/04/2005
VELCADE® (Bortezomib) for injection receives european marketing authorisation for second-line use in multiple myeloma patients
More...
01/03/2005
VELCADE® (bortezomib) data confirms long-term survival
More...
Full list...
|
 |
|
|
